Description

(2Z)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-Dihydro-[1,2,4]Triazolo[4,3-A]Pyrazine-7(8H)-Yl]-1-(2,4,5-Trifluorophenyl)But-2-En-2-Amine is a high-purity, advanced pharmaceutical intermediate characterized by its complex heterocyclic structure incorporating a triazolopyrazine core and multiple fluorine substituents. This compound is of significant commercial interest for its role as a key building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly those targeting central nervous system and metabolic disorders. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and API manufacturers engaged in developing next-generation therapeutics.

Application

• Pharmaceutical Intermediate: Critical precursor in the multi-step synthesis of proprietary drug candidates, especially kinase inhibitors and modulators of neurological pathways.
• Research & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and lead optimization processes in drug discovery programs.
• Process Chemistry: Serves as a standard reference material for developing and scaling up robust, GMP-compliant synthetic routes for new chemical entities (NCEs).
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the production of clinical trial materials and commercial API batches.
• Biochemical Research: Potential use as a tool compound or probe in biochemical assays to study specific enzyme or receptor interactions.

Basic Information

Product Name	(2Z)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-Dihydro-[1,2,4]Triazolo[4,3-A]Pyrazine-7(8H)-Yl]-1-(2,4,5-Trifluorophenyl)But-2-En-2-Amine
CAS No.	767340-03-4
Molecular Formula	C₁₇H₁₂F₆N₆O
Molecular Weight	430.31 g/mol
Synonyms	(2Z)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)but-2-en-2-amine; 767340-03-4; UNII-9J8K3A9U4Q; 9J8K3A9U4Q; (Z)-4-Oxo-4-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-1-(2,4,5-trifluorophenyl)but-2-en-2-amine; But-2-en-2-amine, 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)-, (2Z)-
EINECS	Contact for details

Quality Control

Every batch of this pharmaceutical intermediate is produced and tested under a strict quality management system. We provide comprehensive analytical data to ensure identity, purity, and consistency, supporting our clients' regulatory filings. Certificates of Analysis (COA) detailing HPLC purity, related substances, residual solvents, and other critical parameters are supplied with each shipment. Our quality standards are designed to meet the rigorous demands of cGMP (Current Good Manufacturing Practice) for advanced intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability. For long-term storage, consider inert atmosphere packaging to prevent potential degradation.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Any individual impurity ≤ 0.5%; Total impurities ≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.